BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25348618)

  • 1. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.
    Apellániz-Ruiz M; Inglada-Pérez L; Naranjo ME; Sánchez L; Mancikova V; Currás-Freixes M; de Cubas AA; Comino-Méndez I; Triki S; Rebai A; Rasool M; Moya G; Grazina M; Opocher G; Cascón A; Taboada-Echalar P; Ingelman-Sundberg M; Carracedo A; Robledo M; Llerena A; Rodríguez-Antona C
    Pharmacogenomics J; 2015 Jun; 15(3):288-92. PubMed ID: 25348618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
    Garsa AA; McLeod HL; Marsh S
    BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional gene variants of CYP3A4.
    Werk AN; Cascorbi I
    Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
    Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
    Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of CYP3A4 genetic polymorphisms in Han Chinese.
    Zhou Q; Yu X; Shu C; Cai Y; Gong W; Wang X; Wang DM; Hu S
    J Hum Genet; 2011 Jun; 56(6):415-22. PubMed ID: 21412247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.
    Yousef AM; Bulatova NR; Newman W; Hakooz N; Ismail S; Qusa H; Zahran F; Anwar Ababneh N; Hasan F; Zaloom I; Khayat G; Al-Zmili R; Naffa R; Al-Diab O
    Mol Biol Rep; 2012 Oct; 39(10):9423-33. PubMed ID: 22722998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.
    Liu CH; Peck K; Huang JD; Lin MS; Wang CH; Hsu WP; Wang HW; Lee HL; Lai ML
    Pharmacogenomics; 2005 Oct; 6(7):731-47. PubMed ID: 16207150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
    Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
    Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
    Lee SJ; Bell DA; Coulter SJ; Ghanayem B; Goldstein JA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):302-9. PubMed ID: 15634941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.
    Berno G; Zaccarelli M; Gori C; Tempestilli M; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
    BMC Med Genet; 2014 Jul; 15():76. PubMed ID: 24986243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Functional Assessment of Eight
    Qi Y; Yang H; Wang S; Zou L; Zhao F; Zhang Q; Hong Y; Luo Q; Zhou Q; Geng P; Chen H; Ji F; Cai J; Dai D
    Drug Metab Dispos; 2024 Feb; 52(3):218-227. PubMed ID: 38195522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients.
    Furuse M; Hosomi S; Nishida Y; Itani S; Nadatani Y; Fukunaga S; Otani K; Tanaka F; Nagami Y; Taira K; Kamata N; Watanabe T; Watanabe K; Fujiwara Y
    PLoS One; 2021; 16(4):e0250597. PubMed ID: 33886687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic analysis of drug metabolizing phase-I enzymes CYP3A4 in Tibetan populations.
    Liu L; Chang Y; Du S; Shi X; Yang H; Kang L; Jin T; Yuan D; He Y
    J Genet; 2017 Jun; 96(2):219-225. PubMed ID: 28674221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
    Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran.
    Azarpira N; Namazi S; Khalili A; Tabesh M
    Mol Biol Rep; 2011 Nov; 38(8):4873-7. PubMed ID: 21153923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variability of CYP3A4 in a heterogeneous Brazilian population from Maranhão.
    Monteiro SC; de Sousa IH; Belfort IK; Nunes JD; Penha BA; dos Santos M; Drumond Louro I; da Silva ID
    Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.
    Hu GX; Dai DP; Wang H; Huang XX; Zhou XY; Cai J; Chen H; Cai JP
    Pharmacogenomics; 2017 Mar; 18(4):369-379. PubMed ID: 28244811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype.
    Lloberas N; Hesselink DA; van Schaik RH; Grinyò JM; Colom H; Gelder TV; Elens L
    Pharmacogenomics; 2018 Mar; 19(4):305-310. PubMed ID: 29469606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.